Promising New Therapy for Hematologic Malignancies in Young Patients
February 28th 2024Alice Bertaina, MD, discusses combining of T-allo10, a donor-derived cell product, with haploidentical stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.
Watch
Survival Benefits Shown After Stem Cell Transplant With Orca-T Vs PTCy
February 26th 2024Orca-T demonstrated survival rates vs post-transplant cyclophosphamide in patients with hematologic malignancies receiving myeloablative conditioning, according to findings from a retrospective analysis.
Read More
Immune Engager Therapies Show Best PFS in RRMM Post CAR T-Cell Therapy
February 23rd 2024A retrospective study of real-world patients showed that immune engager therapies had the best response and progression-free survival rates in patients with multiple myeloma who had a relapse after idecabtagene vicleucel treatment.
Read More
Azoles Given Alongside Ruxolitinib Does Not Impact Efficacy in Acute GVHD
February 23rd 2024Findings from an analysis of the REACH2 study, presented at the 2024 Transplantation & Cellular Therapy Meetings, showed that concomitant treatment with azoles does not impact the safety and efficacy of ruxolitinib for patients with acute graft-vs-host-disease.
Read More
Ciltacabtagene Autoleucel Produces Deep, Durable Responses in Multiple Myeloma
February 23rd 2024In early lines of therapy for relapsed/refractory multiple myeloma, patients receiving cilta-cel demonstrated deep and enduring responses, with overall response rates of 95% and 100% in 2 cohorts.
Read More
Durable Treatment With Ruxolitinib Demonstrated in Real-World cGVHD Population
February 23rd 2024A retrospective study of insurance claims showed patients received ruxolitinib mainly in the second or third line for chronic graft-vs-host disease, with dose adjustment used and no difference shown in time to discontinuation between adult and pediatric patients.
Read More
Ruxolitinib/Belumosudil Combo Leads to 55% Response Rate in GVHD
February 23rd 2024The ruxolitinib and belumosudil combination demonstrated a 55% overall response rate in GVHD, suggesting synergy between inflammatory pathways. The combination was well-tolerated, delayed the need for other therapies.
Read More
Brexu-cel Shows Feasibility in Treating CNS in B-Cell Acute Lymphoblastic Leukemia
February 22nd 2024A retrospective study demonstrated the feasibility and efficacy of brexucabtagene autoleucel in treating central nervous system involvement in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Read More
Tailoring Treatment for High-Risk Bladder Cancer: Beyond BCG
February 2nd 2024In an interview with Targeted Oncology, Stephen Williams, MD, discussed a retrospective cohort study analyzing intravesical gemcitabine usage vs Bacillus Calmette-Guérin for the treatment of high-risk non-muscle invasive bladder cancer.
Read More